Brief

Summary:

The Federal Trade Commission (FTC) announced that it has moved to dismiss its case challenging Sanofi's proposed acquisition of an exclusive license to Maze Therapeutics Inc.'s developmental drug, MZE001, to treat Pompe disease. Sanofi had previously decided to terminate the deal, citing anticompetitive concerns, which would have allowed Sanofi to maintain its monopoly power and charge high prices for treatment. The FTC had alleged that the deal would eliminate a nascent competitor and reduce innovation in the Pompe disease therapy market. With the deal terminated, the FTC will no longer challenge the transaction, and Sanofi and Maze will continue to compete on the merits, potentially leading to more affordable treatment options for patients.

Enforcement

We enforce federal competition and consumer protection laws that prevent anticompetitive, deceptive, and unfair business practices.

View Enforcement

,

Search or browse
the Legal Library

Find legal resources and guidance to understand your business responsibilities and comply with the law.

Browse legal resources

,

Take action

,

Competition Matters

,

John Newman & Amy Ritchie, Bureau of Competition

,

,

Policy

We work to advance government policies that protect consumers and promote competition.

View Policy

,

Search or browse
the Legal Library

Find legal resources and guidance to understand your business responsibilities and comply with the law.

Browse legal resources

,

Take action

,

Technology Blog

,

Nick Jones

,

,

Advice and Guidance

Learn more about your rights as a consumer and how to spot and avoid scams. Find the resources you need to understand how consumer protection law impacts your business.

,

Take action

,

Consumer Advice

,

Business Guidance

,

Servicemembers:
Your tool for financial readiness

Visit militaryconsumer.gov

,

Get consumer protection basics, plain and simple

Visit consumer.gov

,

Learn how the FTC protects free enterprise and consumers

Visit Competition Counts

,

Looking for competition guidance?

Competition Guidance

,

News and Events

,

,


,

Sign up for the latest news

Follow us on social media

         

,

About the FTC

Our mission is protecting consumers and competition by preventing anticompetitive, deceptive, and unfair business practices through law enforcement, advocacy, and education without unduly burdening legitimate business activity.

Learn more about the FTC

,

Looking for legal documents or records? Search the Legal Library instead.

,

Looking for legal documents or records? Search the Legal Library instead.

,

For Release

,

,

Following Sanofi’s decision to terminate its proposed acquisition of an exclusive license to Maze Therapeutics Inc.’s developmental drug to treat Pompe disease, the Federal Trade Commission moved to dismiss its case challenging the transaction. Bureau of Competition Acting Deputy Director Nate Soderstrom issued the following statement:

“Sanofi’s decision not to pursue this anticompetitive transaction is a big win for patients and an important victory for the FTC. The proposed deal would have allowed Sanofi to maintain its monopoly power by eliminating nascent competition, in turn reducing innovation for lifesaving, essential care. The deal also would have enabled Sanofi to continue charging patients monopoly prices of over $750,000 for an annual course of treatment for its Pompe therapies.

Now, with this transaction off the table, Sanofi and Maze can continue to compete on the merits, and both can work to offer patients suffering from this debilitating disease better treatment at affordable prices. This continued incentive to innovate will give patients and their doctors better health care alternatives and ultimately reduce patients’ treatment burden.

The FTC will not hesitate to take action in enforcing the antitrust laws to protect patients. I would like to congratulate and thank all of our incredibly talented staff who worked on this matter. This result would not have been possible without the exceptional skill, hard work, and dedication of staff to the FTC’s mission.”

On December 11, 2023, the FTC sued to block Sanofi’s acquisition of an exclusive license to Maze’s Phase 2-ready developmental drug—a glycogen synthase 1 inhibitor called MZE001— alleging the deal would eliminate a nascent competitor poised to challenge Sanofi’s monopoly in the Pompe disease therapy market. After the FTC issued an administrative complaint and authorized a lawsuit in federal court, Sanofi announced it would terminate its agreement with Maze. The FTC then moved to dismiss its federal court and administrative challenge on December 13, 2023.

,

The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint.  For the latest news and resources, follow the FTC on social mediasubscribe to press releases and read our blog.

,

Office of Public Affairs

,

415-848-5121

Highlights content goes here...

I’d be delighted to provide a comprehensive summary of the provided document, “Enforcement.”” Here is a lengthy summary based on the provided template:

The enforcement division of the Federal Trade Commission (FTC) is responsible for enforcing federal competition and consumer protection laws. The FTC enforces these laws to prevent anticompetitive

Federal Trade Commission

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies